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Abstract
Background: To date different vaginal gel microbicides have been evaluated in phase 2b/3 trials,
but none have demonstrated effectiveness for preventing HIV infection. Failure to demonstrate
effectiveness however does not necessarily indicate that a product is truly inefficacious, as several
sources of efficacy dilution may compromise our ability to identify products that may have been
truly efficacious.
Methods: For four individual sources of dilution, we describe the dilution mechanisms and quantify
the expected effectiveness. An overall expected effectiveness that combines all sources of dilution
in a trial is derived as well.
Results: Under conditions that have been observed in recent microbicide trials, the overall
expected effectiveness assuming an active gel with true efficacy of 50% and 75% are in the range of
[16%; 33%] and [28%; 50%], respectively, when considering the four major sources of dilution. In
contrast the diluting effect due to adherence alone (assuming an adherence of 80%) leads to higher
expected effectiveness, 40% and 60% assuming an active gel with true efficacy of 50% and 75%,
respectively. Individual sources of dilution may demonstrate a small effect when evaluated
independently, but the overall dilution effect in a trial with several sources of dilution can be quite
substantial.
Conclusion:  Currently planned phase 2b/3 microbicide trials of new candidate vaginal
microbicides are not immune from these shortcomings. A good understanding of dilution effects is
necessary to properly interpret microbicide trial results and to identify products worthy of further
development and evaluation. Greater attention should be devoted to reducing and assessing the
impact of efficacy dilution and to carefully selecting the effect size in the design of future trials.
Introduction
The development of female initiated HIV prevention
methods is a high priority. For this reason, several differ-
ent vaginal gel microbicides have been evaluated in phase
2b/3 efficacy trials, but to date none have demonstrated
effectiveness while several have suggested evidence of
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harm. Table S1 reviews the findings of phase 2b/3 micro-
bicide trials completed to date (see Table S1 in additional
file 1). For instance, the cellulose sulfate gel (Ushercell,
Polydex Pharmaceuticals, Toronto, ON, Canada and Top-
ical Prevention of Conception and Disease [TOPCAD],
Chicago, IL, USA) was found to be ineffective in prevent-
ing HIV infection and may also have potentially increased
the risk of HIV acquisition in women [1]. The candidate
microbicide Carraguard (Carraguard/R515, Population
Council, New York, NY, USA) was found to be safe for
vaginal use but ineffective in preventing male-to-female
HIV transmission in a phase 3 trial [2]. More recently the
HPTN-035 trial of 0.5% PRO2000 gel (Endo Pharmaceu-
ticals, Chadds Ford, PA, USA), a viral entry inhibitor,
reported an estimated effectiveness of 30% (95% CI [-8%;
54%]) which, although of borderline significance (p =
0.10), was welcomed with optimism [3]. Results of the
MDP-301 study, a second phase 3 trial of 0.5% PRO2000,
are expected at the end of 2009, and results of other can-
didates are also forthcoming [4].
The outcomes of these microbicide trials deserve a closer
look as failure to demonstrate the effectiveness of a prod-
uct in a phase 2b/3 trial does not necessarily imply that
the product is truly inefficacious. Different "diluting" fac-
tors present in all trials (see Table S1) could compromise
our ability to detect the true efficacy of a microbicide. Fail-
ure to clearly understand the potential impact of the dilu-
tion factors in microbicide trials could lead to
misinterpretation of trial results and the discarding of effi-
cacious products from further evaluation. Thus, it is
important to quantify the relationship between the dilut-
ing factors and the expected reduction in true efficacy in
microbicide trials. The objective of this paper is to assess
the expected magnitude of the efficacy dilution in micro-
bicide trials resulting from the most frequent sources of
dilution, namely product adherence, time off-product due
to pregnancy, HIV infections from anal intercourse and
the inertness of placebo gel. This paper extends the works
of Desai [5], Desai et al [6] and Weiss et al [7] which focus
only on adherence as one potential dilution factor in HIV
prevention trials.
Methods
True Efficacy, Expected and Observed Effectiveness
In order to formulate the relationship between the dilu-
tion factors and effectiveness, we first define our use of the
term efficacy, expected and observed effectiveness. We
define the true efficacy, ET, as the efficacy of a product
used under optimal trial conditions when compared to a
completely inert product. The term observed effectiveness
refers to the intention-to-treat (ITT) estimate obtained
from a trial, i.e. one minus the ratio of the observed HIV
incidence rate in the active gel arm over the incidence in
the placebo arm. The term expected effectiveness is the
expected value of the observed effectiveness (i.e. without
random variability associated with the conduct of a trial).
In absence of any source of bias or dilution, the expected
effectiveness should be equal to the true efficacy. In pres-
ence of dilutions, the expected effectiveness will be less
than the true efficacy. Thus, the dilution effects are
expressed in terms of ET, the true efficacy of a candidate
microbicide (active gel). We describe in Table S2 the
details of the dilution mechanisms of the true efficacy and
the resulting expected effectiveness for each factor acting
alone (Ea, Eo, Es, and Eb) and in combination Eall (see Table
S2 in additional file 2). Without loss of generalisability,
we restrict our analysis to the two arm randomized trial
using a 1:1 allocation. Homogeneity assumptions are
made for simplicity. Although these assumptions might
appear unrealistic, the introduction of more heterogenei-
ties can in some cases amplify the impact of the dilution.
Product Adherence
A proportion, a, of women (adherents) in the trial are
assumed to use the microbicide as prescribed by the pro-
tocol for each vaginal intercourse during the entire follow-
up. This definition implies that non-adherent women
never use the gel during the trial therefore; they do not get
any benefit from the gel as gel is never used. A more real-
istic alternative model might be preferable where women
may use the gel for some acts of vaginal intercourse and
may not for others [7,8]. Under this alternative model,
women using the gel for some but not all of the vaginal
acts would potentially benefit less than those that are
always using the gel. However, the dilution effect under
this alternative model is quite similar to that where
women are either classified as adherent or not adherent.
Product adherence estimates from completed microbicide
trials vary greatly (see Table S1). The high variability
across trials can be partly attributed to different methods
of assessment. Self-reported adherence from face-to-face
interviews tends to over-estimate product adherence
because of social desirability bias [5]. Therefore, most esti-
mates of adherence in Table S1 over-estimate the true pro-
portion of adherent women.
Time Off-Product Due to Pregnancy and Adverse 
Reactions
All candidate vaginal gel microbicides under development
are investigational products without human data on their
safety in pregnancy and to the fetus/embryo. Although,
the product's active ingredients of most candidates are not
absorbed by the genital mucosa, the fetus/embryo may
still be exposed due to the passage of the product through
the uterus and the cervical canal [4]. Given that harm from
the product cannot be entirely ruled out, microbicide pro-
tocols have cautiously address the issue (1) by excluding
women who have the intention of becoming pregnantEmerging Themes in Epidemiology 2009, 6:5 http://www.ete-online.com/content/6/1/5
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during the trial or requiring women to use at least one or
two contraceptive methods and (2) by temporarily with-
drawing the product from women becoming pregnant
during the trial with product use resuming after pregnancy
[9]. Despite these precautions, pregnancies occurring dur-
ing follow-up have lead to high proportion of follow-up
without product use in many trials. Pregnancy rates
between 16 and 64 per 100 woman-years have been
observed in microbicide trials which can lead to a propor-
tion of follow-up time off-product between 5% and 20%
[9]. Although a product can also be withdrawn from
women for other reasons such as the occurrence of
adverse reactions, the dilution effect is negligible because
the time off-product due to other emerging conditions is
substantially smaller than the one due to pregnancy. Thus,
we assume that a proportion, o, of total follow-up time
will be off product due to pregnancy.
Anal Intercourse (AI) as a Source of HIV Infection
Most candidate microbicides currently under develop-
ment aim to prevent transmission from vaginal inter-
course such that most protocols prohibit the use of these
products for AI as well as counseling participants to
abstain from unprotected receptive AI. Thus, we assume
that a proportion, s, of HIV infection endpoints was
acquired from unprotected receptive AI. Due to the sensi-
tive nature of this practice, the prevalence of unprotected
AI has been notoriously hard to estimate and is believed
to be greatly under-estimated both in trials and in behav-
ioral surveys. A NSFG 2002 survey has estimated that 34%
of US women reported having AI with an opposite sex
partner in their lifetime [10]. In contrast, among sexually
experienced South African youth, 5.3% of women
reported ever engaging in AI [11]. In completed trials, the
reported rate of ever having AI varies between 14% in a
lifetime to about 2% in the past month (see Table S1).
Such large differences are due partly to variation across
clinical sites and to the data collection methods used to
capture sensitive behavior. Therefore, these trial estimates
of AI are most likely under-estimating the true frequency
of AI.
Placebo Physical Barrier/Lubrication Effect
Up to five different placebo gels have been used in micro-
bicide trials, many of which may not be completely inert
[4]. For instance, the methycellulose gel used as the pla-
cebo in the Carraguard trial may have acted as a physical
barrier and reduced HIV acquisition [12,13]. Further-
more, given the potential role of the vaginal pH on trans-
missibility of HIV, it is somewhat problematic that active
gel and placebo have different pH levels affecting the vag-
inal flora in presence of semen. For example, the placebo
gel used in the cellulose sulfate trials has a pH level of 4.4
compared to a pH level of 7.5 for the cellulose sulfate gel.
If truly effective in reducing HIV acquisition, the efficacies
of the placebo gels currently used in microbicide trials are
believed to be relatively small (Ep< 10%). For instance, the
HPTN-035 trial observed an hazard risk ratio of 0.97
(95% CI [0.66;1.44]) when comparing the placebo gel to
the 'no gel' arm (although condom use was significantly
higher in the 'no gel' arm).
Total Dilution Effect and Overall Expected Effectiveness
In a given microbicide trial, some or all of the above dilu-
tion factors will be present. If we assume a weak or no
association between pregnancy risk, adherence, and fre-
quency of unprotected receptive AI, the overall expected
effectiveness Eall can be derived using the natural ordering
described in Table S2. However, if women engaging in
unprotected AI were also lower gel users (i.e. non-adher-
ent) and had higher pregnancy rates, then the dilution
effects would be concentrated among a relatively small
proportion of participants. This clustering would lead to a
total dilution effect that would be smaller than the one
obtained under our weakly dependent model. However,
we argue that this strong clustering is unlikely since if dilu-
tion factors were highly correlated this would also mean
that most trial participants would be highly adherent, not
engage in unprotected receptive AI, and have very low
rates of pregnancy; an association that has not been
observed in trials. The total expected efficacy dilution (D)
is simply the percent reduction between the true efficacy
of the product ET and the expected effectiveness in a rand-
omized controlled trial (Eall).
Results
The target adherence when designing microbicide trials
has often been set to achieve at least '80%', which is
higher than the observed adherence depending on the
assessment methods (see Table S1). For this level of
adherence the expected effectiveness Ea is 40.0% when the
true efficacy of the active gel is 50% (Figure 1A). Similarly,
20% of follow-up time off-product due to pregnancy
yields an expected effectiveness Eo of 40.0% (Figure 1C).
In a trial where 15% of the observed HIV endpoints come
from unprotected AI, the expected effectiveness Es would
be 44.2% (Figure 1B). Finally, if the placebo gel has an
efficacy Ep of 10%, the expected effectiveness Eb is 44.4%
(Figure 1D). Therefore, using these values for the dilution
parameters, the percent reduction in efficacy D  for an
active gel with a 50% true efficacy ranges between 11.2%
and 20.0%. The corresponding dilution ranges for an
active gel with true efficacy of 25% and 75% are [13.3%-
33.3%] and [3.7%-20.0%], respectively. The expected
dilution will be more pronounced for smaller true effica-
cies ET for the dilution effect due to placebo efficacy and
AI. For the latter the difference is not substantial, but for
the former the dilution effect will be more substantial,
especially when the true efficacy ET is relatively close to the
efficacy of the placebo Ep.Emerging Themes in Epidemiology 2009, 6:5 http://www.ete-online.com/content/6/1/5
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Using different values for the dilution parameters, we
have constructed four scenarios to investigate the total
dilution effect when all four sources of dilution are taken
into account (see Table S3 in additional file 3). Scenario 1
represents the somewhat ideal microbicide trial with very
high adherence, low pregnancy, small proportion of HIV
infections from AI, and no placebo efficacy. Scenarios 2
and 3 reflect data from completed microbicide trials
(Table S1) and from field studies (frequency of AI),
although estimates for adherence and AI obtained from
trials are likely over- and underestimated, respectively
[7,9,11]. We have set the placebo efficacy at 0% and 5%
for these scenarios since there are no data available for
many of the different placebo gels that we used in the
completed trials. Scenario 4 represents an extreme but not
unrealistic example of a trial with strong dilution effects
from all sources. The results for the total dilution effect D
and the overall expected effectiveness Eall are also pre-
sented in Figure 2. For the most optimistic scenarios 1 and
2, the total dilution effects are in the range of [17.2%-
Expected effectiveness for different source of dilution Figure 1
Expected effectiveness for different source of dilution. For different level of true efficacy of a candidate microbicide; ET 
= 25%, 50%, and 75%; Panel A shows the results for the dilution due to adherence (Ea), Panel B shows the results for the dilu-
tion due to HIV infections from anal intercourse (Es), Panel C shows the results for the dilution from time off-product due to 
pregnancy (Eo), and Panel D shows the results for the dilution due to the efficacy of the placebo gel (Eb).Emerging Themes in Epidemiology 2009, 6:5 http://www.ete-online.com/content/6/1/5
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18.3%] and [32.7%-34.4%], respectively, while for sce-
narios 3 and 4, D  ranges from [49.2%-58.8%] and
[63.0%-76.6%], respectively.
Assuming that the true efficacy of an active gel is 50%
under scenarios 3 and 4, the overall expected effectiveness
Eall are 33.2% and 23.8%, respectively, a range below what
trials typically have been powered to detect. Under the
more extreme scenario 4, the overall expected effective-
ness is only 16.3% while it is 41.3% under the ideal sce-
nario 1. Importantly, although the latter appears small,
the effect is substantial when put in terms of statistical
power. For instance, 66 HIV endpoints are required to
achieve 80% power with a 2.5% false positive error rate in
a 2-arm trial in order to detect a 50% effectiveness while
an additional 45 HIV endpoints (for a total of 111) are
required to detect an effectiveness of 41.3% instead of
50%. An increase of 45 HIV endpoints would require a
substantial amount of additional resources.
Discussion
Effectiveness trials for vaginal gel microbicides have sev-
eral sources of efficacy dilution, most or all of which are
present in trials that have been completed so far. We have
illustrated that when all these sources of dilution are
present within the same trial, a substantial dilution of the
true microbicide efficacy may ensue. Under the levels of
dilution reported from completed microbicide trials the
overall expected effectiveness will be in the range of 24%
and 33% when the true efficacy of active gel is 50%. Under
more severe dilution conditions, the expected effective-
ness could be as low as 16%.
Our analysis has several limitations. Our model is simple
and relies on an assumption of weak association between
the different dilution factors. Although more complex
models could be developed, it would require several
assumptions on the relationships between the different
sources of dilution. Those additional assumptions could
be justified on the basis of the associations observed in
microbicide trials. Nevertheless, our findings on the dilu-
tion effect due to adherence alone replicate those by Weiss
et al [7] obtained using a different model. For 80% adher-
ence and true efficacies of 25%, 50%, and 75%, they have
obtained expected effectiveness of 18%, 37%, and 57%,
respectively, compared to 20%, 40%, and 60% under our
model. Therefore, the use of the Weiss et al model for the
dilution due to low adherence would lead to slightly
larger dilution effect. Our definition of adherence
includes women who are using the gel inside the appro-
priate time interval before intercourse as prescribed by the
protocol (e.g., within two hours prior to intercourse) and
assumes that the efficacy of a product used outside the
time interval would be greatly diminished or even com-
Overall expected effectiveness and total dilution effect Figure 2
Overall expected effectiveness and total dilution effect. For the four different scenarios described in Table S3 (see 
Table S3 in additional file 3) and as a function of the true efficacy of a candidate microbicide (ET), Panel A shows the results for 
the overall expected effectiveness (Eall) and Panel B shows the results for the total dilution effect (D).Emerging Themes in Epidemiology 2009, 6:5 http://www.ete-online.com/content/6/1/5
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pletely eliminated. To our knowledge, no reliable data is
available on gel applications that are outside the time
interval, but further dilution can occur if gel users are not
using the product within the correct time interval. As well,
we have not considered other potential dilution factors
such as product sharing among trial participants who are
assigned to different arms of the trial. Only anecdotal evi-
dence has been reported so far, and data on product shar-
ing remains scarce or even inexistent. In addition, further
dilution of efficacy can result from a strong association
between condom use and microbicide use as described in
Trussell and Dominik [14]. Given the high efficacy of con-
doms, most of the HIV infections that are observed in a
trial are from vaginal (or anal) intercourse unprotected by
condoms. Therefore, a positive association between con-
dom and gel use would lead to stronger dilution effects
than those presented in this manuscript. Similarly, other
behavioral factors which affect adherence might lead to
stronger/weaker dilution effects. For instance, if gel users
tend to be not very sexually active then stronger dilution
effect might be expected since most of the HIV infections
in the trial will happen among sexually active women.
Importantly, dilution effects could also reduce the effect
of a (truly) harmful product which increases the risk of
HIV infections. Thus, some of the candidate microbicides
which have been show to increase the risk of HIV acquisi-
tion may have been more harmful than what was
observed in these trials.
A case in point is the Carraguard trial which specifically
discussed and attributed the lack of effectiveness to low
adherence, HIV infections from AI, and the potential effi-
cacy of the placebo gel used in the trial [2]. Based on a
staining assay technique, they have estimated the adher-
ence in the trial to be only 42% (although this estimate
might be an under-estimate [15]). Assuming a true effi-
cacy of 50% in our model, an overall expected effective-
ness of only 14.9% is obtained with an adherence of 40%,
20% of HIV infections from AI, a placebo efficacy of 10%,
and 0% time off-product (pregnant women were discon-
tinued permanently from this trial). The observed effec-
tiveness in the trial was 13% (95% CI [-9%:31%]). Given
the potential amount of efficacy dilution in the trial, there
was very little chance of detecting the effectiveness of the
product if the true efficacy of Carraguard was in the range
of 40%-60%. Furthermore, if the true efficacy was in the
range of 75%, the overall expected effectiveness under our
model would be only 25%, which remains much lower
than the 33% the trial was powered to detect. Therefore, if
Carraguard was truly moderately efficacious it is highly
unlikely that this trial could have detected it. As a conse-
quence of its observed effectiveness, Carraguard may well
be discarded from the development pipeline. However, it
is interesting to speculate whether it would meet the same
fate had it been evaluated under more controlled sources
of dilution.
Even though a moderately effective microbicide (30% to
50%) may not be sufficient to eradicate the HIV epidemic,
it is nevertheless important to measure the extent of dilu-
tion to identify potentially efficacious products for further
development, particularly as several moderately effective
products with different mechanisms of action could be
combined into a single very effective product (e.g., com-
bining a barrier with an entry inhibitor).
Currently planned trials for new candidate microbicides
have not fully resolved the problems related to dilution.
To reduce the impact of time off-product due to preg-
nancy, some trials are now requiring that women use two
methods of contraception before being allowed to enroll.
Given the lack of safety data, it is not possible to allow
women to remain on-product while pregnant. However,
safety microbicide studies on pregnant women are cur-
rently on-going and more are being planned but it will
take several years before the results become available from
these studies.
Optimizing product adherence is essential. One key issue
is the lack of a reliable assessment tool. So far, most of the
assessment tools used in microbicide trials have relied on
self-reported product use obtained via face-to-face inter-
views, which has been shown to produce over-estimation
of adherence. Newly designed microbicide trials are plan-
ning to assess adherence using better assessment tools
(e.g., audio computer-assisted self-interview) in order to
increase the validity of the adherence data, which may
also help to develop strategies to maximize and optimize
adherence.
As with adherence, greater effort should be placed to use
validated tools to collect data on AI. The dilution effect
due to HIV infections that are not from vaginal inter-
course is potentially large. Trial data cannot distinguish
between anal and vaginal transmission. It is therefore
important to improve estimates of the frequency of
unprotected AI and to greatly intensify the counseling
message to reduce the practice of unprotected AI during
the trial. Ultimately, the best option would be to have a
candidate product that can be used vaginally and anally as
it would potentially provide the greatest benefit. Develop-
ment of microbicides for AI is currently underway
although most products are for vaginal use only.
A suggestion to control for all these different sources of
dilutions is that the ITT analysis should not be the primary
analysis in a microbicide trial and that so called 'per-pro-
tocol' analysis should be used where non-adherent
women and time off-product are excluded from the anal-Emerging Themes in Epidemiology 2009, 6:5 http://www.ete-online.com/content/6/1/5
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ysis. We think that this is not a viable solution as it is prob-
lematic for two reasons. First, the benefit induced by
randomization under an ITT analysis often outweighs
what can be gained from a non-ITT analysis. For this rea-
son, regulators (such as FDA) typically put a lot of weight
on the ITT analysis. It is difficult to foresee how a candi-
date microbicide could be marketed solely based on its
favorable results on a 'per-protocol' analysis with non-sig-
nificant ITT results. Second, exclusion from the analysis of
non-adherent women and/or of women engaging in
unprotected AI needs to be done with a validated tool for
assessing adherence and risk behaviors which has proven
to be a great challenge so far.
Finally, a careful selection of the effect size to be detected
in light of the potential dilution factors should be made
in the planning of future trials. Protocol teams have used
different effect size as it can be seen in past microbicide
trial designs where efficacy varying from 30% to 50% have
been used to determine the sample size.
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